Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP-Reference-Cited by-同舟云学术

Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP

Published:2021-12 Issue:12 Volume:9 Page:4477-4479
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Briegel Ignaz,Felicio-Briegel Axelle,Mertsch Pontus,Kneidinger Nikolaus,Haubner Frank,Milger Katrin^ORCID

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference8 articles.

1. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma;Eger;J Allergy Clin Immunol Pract,2021

2. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy;Mümmler;J Allergy Clin Immunol Pract,2021

3. Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics;Renner;Immun Inflamm Dis,2021

4. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials;Bachert;Lancet,2019

5. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials;Gevaert;J Allergy Clin Immunol,2020

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

2. Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis;Journal of Asthma and Allergy;2024-06

3. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis;Autoimmunity Reviews;2024-03

4. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence;Expert Opinion on Biological Therapy;2024-01-30

5. Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study;European Archives of Oto-Rhino-Laryngology;2023-12-29